Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.…
Agenus' Q3 Earnings Match Estimates, Revenues Miss Mark, Stock Down
Agenus (NASDAQ: AGEN) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 81 employees.
The shares were at 5.970 USD on 20 November 2026, up 60.1% over 52 weeks. Its 52-week range is 2.710 USD to 10.31 USD: the price is 42.1% below the high and 120.3% above the low.
At a market capitalisation of 270.12M USD, it trades at 26.0 times trailing earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a discount of 22% for AGEN.
Agenus reports return on equity of -0.0%, an operating margin of 38.9% and revenue up 4.1% year over year.
It holds more cash than debt, a net cash position of 47.47M USD. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. The next earnings report is expected on 15 March 2027.